Publications by authors named "Catherine A Azar"

Claim this Profile
L
Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41.
Priya Rastogi, Gong Tang, Saima Hassan, Charles E Geyer, Catherine A Azar

Breast Cancer Res Treat· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
André Robidoux, Gong Tang, Priya Rastogi, Charles E Geyer, Catherine A Azar

Lancet Oncol· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.
Sandra M Swain, Gong Tang, Charles E Geyer, Priya Rastogi, James N Atkins, Catherine A Azar

J Clin Oncol· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer.
Edward H Romond, Jong-Hyeon Jeong, Priya Rastogi, Sandra M Swain, Charles E Geyer, Catherine A Azar

J Clin Oncol· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.
Carmen J Allegra, Greg Yothers, Michael J O'Connell, Saima Sharif, Nicholas J Petrelli, Catherine A Azar

J Clin Oncol· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2).
Bruno C Medeiros, Holbrook E Kohrt, Daniel A Arber, Charles D Bangs, Athena M Cherry, Catherine A Azar

Leuk Res· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer.
Carmen J Allegra, Greg Yothers, Michael J O'Connell, Saima Sharif, Linda H Colangelo, Catherine A Azar

J Clin Oncol· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis